Erschienen in:
11.06.2020 | Preclinical study
PIBF1 suppresses the ATR/CHK1 signaling pathway and promotes proliferation and motility of triple-negative breast cancer cells
verfasst von:
Eun Ji Ro, Seung-Hee Ryu, Eun-Young Park, Je-Won Ryu, Sang Jun Byun, Seung-Ho Heo, Kang Hyun Kim, In-Jeoung Baek, Byung Ho Son, Sang-Wook Lee
Erschienen in:
Breast Cancer Research and Treatment
|
Ausgabe 3/2020
Einloggen, um Zugang zu erhalten
Abstract
Purpose
This study evaluates the oncogenic role of PIBF1 in triple-negative breast cancer (TNBC). TNBC is considered to have a poorer prognosis than other types of breast cancer and is associated with high risk of recurrence and distant metastasis. Currently, there are no effective therapies for the TNBC patients with distant metastasis due to the lack of targeted therapeutic options.
Methods
The effects of PIBF1 knockdown on the cell viability and motility of TNBC cell lines were investigated. Effects of PIBF1 overexpression on tumorigenicity and cell motility were confirmed using Ba/F3 cell line and xenograft study on BALB/c nude mice.
Results
In TNBC cell lines that highly express PIBF1, knockdown of PIBF1 induces apoptosis and suppresses cell viability and motility with activation of the ATR/CHK1 signaling pathway. Moreover, the oncogenic function of PIBF1 was confirmed using the Ba/F3 cell line.
Conclusion
For the first time, these findings clarify the role of PIBF1 in regulating ATR/CHK1 signaling pathway and inhibiting the proliferation and migration of TNBC cell lines. These results demonstrate the oncogenic roles of PIBF1 and provide new insights into the function and the molecular mechanism of PIBF1 in malignant TNBC.